Recruiting

hemoTAG

Sponsor:

Aventusoft, LLC.

Code:

NCT06567795

Conditions

Diabetes Mellitus Type 2

Cardiovascular Diseases

Coronary Artery Disease

Cerebrovascular Disease

Peripheral Artery Disease

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Hemotag

Study Details

Brief summary:

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Conditions

Diabetes Mellitus Type 2

Cardiovascular Diseases

Coronary Artery Disease

Cerebrovascular Disease

Peripheral Artery Disease

Study ID

NCT06567795

Start date

Mar 14, 2024

Status verified date

Aug, 2024

Completion date

Mar 18, 2027

Anticipated

Primary completion date

Mar 18, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adult patients older than 40 years of age.
2. Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years.
3. Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc...) --OR--

Have one (1) of the following concomitant medical diagnoses:
1. Diabetic Retinopathy (proliferative or non-proliferative)
2. Diabetic Nephropathy (eGFR \<60 mL/min/1.73m2 and/or urine albumin/creatinine ratio ≥30 mg/g)
3. Diabetic Neuropathy
4. Elevated High-sensitivity C-reactive protein (hs-CRP) --AND--

Have a history of two (2) or more of the following:
5. Diagnosis of Hypertension for at least 6 months or more (treated or untreated)
6. Hypercholesterolemia (LDL-C \>100 mg/dL)
7. Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women)
8. History of Smoking
4. Willingness to undergo HEMOTAG evaluation.
5. Willingness to undergo Standard of Care visits/assessments and NT-pro BNP lab evaluations.
6. Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period.
7. Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol
8. Able to give informed consent.

Exclusion Criteria:

1. Terminal condition with life expectancy less than 12 months as determined by investigator.
2. Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.
3. Illness/ Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).
4. Participant enrolled in another interventional study (observational or registries are not excluded).
5. Prisoners and wards of the state.
6. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\'s assessment.
7. Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)
8. Inability to provide informed consent (Must speak English).
9. Women who are pregnant or are planning to become pregnant during the study.
10. Women of childbearing potential who are unwilling or unable to comply with contraception measures.

Study Design

Enrollment

189 participants

Anticipated

Interventions and Outcome Measures

Arms

HEMOTAG with Standard of Care in DM patients

HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.

Interventions

Hemotag

Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days

Primary outcome measure

  • To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration. [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

Metabolic Research Institute, Inc

Recruiting

West Palm Beach, Florida, United States, 33401'

Contacts

Principal Investigator:

Barry Horowitz, MD

More Information

Sponsor

Aventusoft, LLC.

Last update posted

Aug 23, 2024

Last verified

Aug, 2024

Keywords

  • Diabetes Mellitus
  • Cardiovascular Diseases
  • Coronary Artery Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Aventusoft, LLC. on 2024-08-23.